Yung-Jue Bang, MD, PhD, of Seoul National University Hospital, discusses phase III study findings on olaparib and paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy. (Abstract LBA25)
Shou-Ching Tang, MD, PhD, of the Georgia Cancer Center, discusses findings on a novel peptide–paclitaxel conjugate that crosses the blood-brain barrier and shows activity in breast cancer patients with recurrent central nervous system metastases. (Abstract 324O)
Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses in French his findings on the high rates of chemotherapy used at the end of life for metastatic solid cancer, especially in young patients treated in high-volume centers without a palliative care unit. (Abstract 1300O)
Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses in Italian overall survival and safety results from a phase 3 trial of ipilimumab at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma. (Abstract 1106O)
Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses in French phase III findings on a comparison of atezolizumab with docetaxel in patients with advanced non-small cell lung cancer. (Abstract LBA44)
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on cabozantinib vs sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor and intermediate risk. (Abstract LBA30) Follow him on Twitter: @DrChoueiri
